The role of proprotein convertase subtilisin/kexin type 9 inhibitors in managing cardiovascular risk
Hypercholesterolaemia and dyslipidaemia, marked by decreased levels of high-density lipoprotein and elevated levels of lowdensity lipoprotein (LDL), increase the risk of cardiovascular disease. Familial hypercholesterolaemia (FH), diagnosed based on the clinical features seen in patients with a posi...
Saved in:
| Main Authors: | Natalie Schellack, Gustav Schellack, E. Bronkhorst |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AOSIS
2016-01-01
|
| Series: | South African Family Practice |
| Subjects: | |
| Online Access: | https://safpj.co.za/index.php/safpj/article/view/4439 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
ASSOCIATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 WITH HYPERTENSION AND SMOKING
by: K. S. Benimetskaya, et al.
Published: (2019-03-01) -
Levels of proprotein convertase subtilisin/kexin type 9 in patients with acute myocardial infarction
by: A. D. Gimadeeva, et al.
Published: (2020-03-01) -
Proprotein convertase subtilisin/kexin type 9: a promising marker of cardiovascular risk in post-menopausal diabetic women in primary prevention
by: Michelangelo Rottura, et al.
Published: (2025-03-01) -
Natural phytochemicals as small-molecule proprotein convertase subtilisin/kexin type 9 inhibitors
by: Je-Wen Liou, et al.
Published: (2024-09-01) -
Oral and Non-Oral Cholesterol-Lowering Drugs with PCSK9 and Other Biomolecules as Targets: Present Status and Future Prospects
by: Ajoy Basak
Published: (2025-03-01)